{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:50:09Z","timestamp":1771030209848,"version":"3.50.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"22","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Hepatitis B surface antigen (HBsAg) clearance is vital for a functional cure of hepatitis B virus (HBV) infection. However, the incidence and predictors of HBsAg seroclearance in patients co-infected with HBV and human immunodeficiency virus (HIV) remain largely unknown in Guangdong, China.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Between 2009 and 2019, patients co-infected with HBV\/HIV undergoing antiretroviral therapy (ART) in Guangzhou Eighth People's Hospital affiliated to Guangzhou Medical University were retrospectively reviewed with the endpoint on December 31, 2020. The incidence and risk factors for HBsAg seroclearance were evaluated using Kaplan\u2013Meier and multivariate Cox regression analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 1550 HBV\/HIV co-infected patients were included in the study, with the median age of 42 years and 86.0% (1333\/1550) males. Further, 98.3% (1524\/1550) received ART containing tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC). HBV DNA was examined in 1283 cases at the last follow-up. Over the median 4.7 years of follow-up, 8.1% (126\/1550) patients achieved HBsAg seroclearance, among whom 50.8% (64\/126) obtained hepatitis B surface antibody, 28.1% (137\/488) acquired hepatitis B e antigen seroconversion, and 95.9% (1231\/1283) undetectable HBV DNA. Compared with patients who maintained HBsAg positive, cases achieving HBsAg seroclearance showed no differences in age, gender, CD4<jats:sup>+<\/jats:sup> T cell count, alanine aminotransferase (ALT) level, or fibrosis status; however, they presented lower HBV DNA levels, lower HBsAg levels, and higher rates of HBV genotype B at the baseline. Multivariate analysis showed that baseline HBsAg &lt;1500 cutoff index (COI) (adjusted hazard ratio [aHR], 2.74, 95% confidence interval [95% CI]: 1.48\u20135.09), ALT elevation &gt;2 \u00d7 upper limit of normal during the first six months after receiving ART (aHR, 2.96, 95% CI: 1.53\u20135.77), and HBV genotype B (aHR, 3.73, 95% CI: 1.46\u20139.59) were independent predictors for HBsAg seroclearance (all <jats:italic toggle=\"yes\">P<\/jats:italic> &lt;0.01).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Long-term TDF-containing ART has high anti-HBV efficacy including relatively high overall HBsAg seroclearance in HBV\/HIV co-infected patients. Lower baseline HBsAg levels, HBV genotype B, and elevated ALT levels during the first six months of ART are potential predictors of HBsAg seroclearance.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000002886","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T09:05:39Z","timestamp":1698311139000},"page":"2686-2693","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV\/HIV during antiretroviral therapy in Guangdong, China"],"prefix":"10.1097","volume":"136","author":[{"given":"Yaozu","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huolin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengle","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"R1-20250602","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","article-title":"Global reporting of progress towards elimination of hepatitis B and hepatitis C","volume":"8","author":"Cui","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R2-20250602","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/cid\/ciz1170","article-title":"Global burden of hepatitis B infection in people living with human immunodeficiency virus: a systematic review and meta-analysis","volume":"71","author":"Leumi","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R3-20250602","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/cid\/cis432","article-title":"Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection","volume":"55","author":"Falade-Nwulia","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R4-20250602","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/hep.31839","article-title":"Risk of HCC with hepatitis B viremia among HIV\/HBV-coinfected persons in North America","volume":"74","author":"Kim","year":"2021","journal-title":"Hepatology"},{"key":"R5-20250602","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3390\/v13071341","article-title":"Functional cure of hepatitis B virus infection in individuals with HIV-coinfection: a literature review","volume":"13","author":"Boyd","year":"2021","journal-title":"Viruses"},{"key":"R6-20250602","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jhep.2004.10.026","article-title":"Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance","volume":"42","author":"Ahn","year":"2005","journal-title":"J Hepatol"},{"key":"R7-20250602","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/hep.21612","article-title":"HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up","volume":"45","author":"Chu","year":"2007","journal-title":"Hepatology"},{"key":"R8-20250602","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1053\/j.gastro.2010.04.048","article-title":"Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study","volume":"139","author":"Liu","year":"2010","journal-title":"Gastroenterology"},{"key":"R9-20250602","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"R10-20250602","doi-asserted-by":"crossref","first-page":"e0215464","DOI":"10.1371\/journal.pone.0215464","article-title":"Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV\/HIV co-infection","volume":"14","author":"Gantner","year":"2019","journal-title":"PLoS One"},{"key":"R11-20250602","first-page":"2744","article-title":"High rates of hepatitis B virus (HBV) functional cure among HIV\/HBV coinfected Chinese adults on antiretroviral therapy","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J"},{"key":"R12-20250602","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology"},{"key":"R13-20250602","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/jvh.13212","article-title":"Long-term observation on hepatitis B surface antigen seroclearance in therapy experienced HIV\/HBV co-infected Chinese","volume":"27","author":"Yang","year":"2020","journal-title":"J Viral Hepat"},{"key":"R14-20250602","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s12072-019-09956-1","article-title":"Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study","volume":"13","author":"Wu","year":"2019","journal-title":"Hepatol Int"},{"key":"R15-20250602","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J Hepatol"},{"key":"R16-20250602","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0168-8278(00)80135-X","article-title":"Hepatitis B genotypes and the response to interferon therapy","volume":"33","author":"Kao","year":"2000","journal-title":"J Hepatol"},{"key":"R17-20250602","first-page":"1425","article-title":"HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C","volume":"36","author":"Wai","year":"2002","journal-title":"Hepatology"},{"key":"R18-20250602","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hep.30231","article-title":"Hepatitis B virus core variants, liver fibrosis, and hepatocellular carcinoma","volume":"69","author":"Ligat","year":"2019","journal-title":"Hepatology"},{"key":"R19-20250602","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jmv.21049","article-title":"Relationship of serological subtype, basic core promoter and precore mutations to genotypes\/subgenotypes of hepatitis B virus","volume":"80","author":"Kramvis","year":"2008","journal-title":"J Med Virol"},{"key":"R20-20250602","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/jvh.12914","article-title":"Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa","volume":"25","author":"Boyd","year":"2018","journal-title":"J Viral Hepat"},{"key":"R21-20250602","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.jhep.2014.08.033","article-title":"Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management","volume":"61","author":"Chang","year":"2014","journal-title":"J Hepatol"},{"key":"R22-20250602","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1742-6405-9-6","article-title":"Assessment of HBV flare in a randomized clinical trial in HIV\/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand","volume":"9","author":"Avihingsanon","year":"2012","journal-title":"AIDS Res Ther"},{"key":"R23-20250602","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/infdis\/jiaa662","article-title":"Impact of immune reconstitution-induced hepatic flare on hepatitis B surface antigen loss in hepatitis B virus\/human immunodeficiency virus-1 coinfected patients","volume":"223","author":"Yoshikawa","year":"2021","journal-title":"J Infect Dis"},{"key":"R24-20250602","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S2468-1253(19)30344-9","article-title":"Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad","volume":"5","author":"Ghany","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R25-20250602","first-page":"592","article-title":"Differential response of HBV envelope-specific CD4+ T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy","volume":"78","author":"Li","year":"2023","journal-title":"Hepatology"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002886","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T23:01:51Z","timestamp":1748905311000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":25,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000002886","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,25]]},"assertion":[{"value":"2023-07-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}